IBRANCE Is Taken With A Hormonal Therapy
A portion of this content was originally sourced from: ibrance.com
Topic: Metastic Breast Cancer Research & Information
Summary: Our team just found a very interested article about IBRANCE® (palbociclib), a medicaction that may inhibit cell growth and division in hormone receptor positive, HER2- metastatic breast cancer.
Please RT. We need @pfizer & @NICEcomms to work together to make pioneering drug #palbociclib (Ibrance) available.
> https://t.co/NcpgUp00w4 pic.twitter.com/hcfFgqZeSW— Breast Cancer Now (@breastcancernow) February 24, 2017
According to Ibrance.com, the first FDA-approved medication in a class of therapy called CDK 4/6 inhibitors. Taken in combination with certain hormonal therapies, IBRANCE works to put the brakes on cell growth and division in hormone receptor positive, HER2- metastatic breast cancer.
IBRANCE is taken with hormonal therapy and is used to treat hormone receptor positive, HER2- metastatic breast cancer. In combination with letrozole (sometimes called Femara®), IBRANCE is for postmenopausal women as their first hormonal based therapy. In combination with fulvestrant (known as Faslodex®), IBRANCE is for women who have previously received hormonal therapy for their disease. Talk to your healthcare team to learn if IBRANCE is right for you.
Which Type Of Breast Cancer Is IBRANCE For?
IBRANCE is for women with hormone receptor positive (HR+), HER2- metastatic breast cancer — or HR+/HER2-.
If your subtype is HER2-, your cancer cells have less HER2 protein expression and, therefore, are less likely to respond to anti-HER2 therapies.
Hormone receptor positive includes both ER+ (estrogen receptor positive) and/or PR+ (progesterone receptor positive) subtypes.
Hormone receptor positive (HR+), HER2- is the most common subtype of breast cancer, representing roughly 73% of all cases. If your subtype is ER+ and/or PR+, you’re more likely to respond to hormone therapies, like letrozole or fulvestrant, that reduce the effects of hormones.
Femara is a registered trademark of Novartis Corporation.
Faslodex is a registered trademark of the AstraZeneca group of companies.
Although not a huge increase, a new study found menopausal hormone therapy raises the risk for fecal incontinence https://t.co/OOux8ue9PB pic.twitter.com/tF8PfSVfsg
— Medscape (@Medscape) February 27, 2017
